

Gabriele Madonna

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2105339/publications.pdf>

Version: 2024-02-01

54
papers

1,741
citations

394421

19
h-index

361022

35
g-index

56
all docs

56
docs citations

56
times ranked

3607
citing authors

#	ARTICLE	IF	CITATIONS
1	Dermatologic adverse events associated with targeted therapies for melanoma. Expert Opinion on Drug Safety, 2022, 21, 385-395.	2.4	0
2	Altered Frequencies and Functions of Innate Lymphoid Cells in Melanoma Patients Are Modulated by Immune Checkpoints Inhibitors. Frontiers in Immunology, 2022, 13, 811131.	4.8	6
3	Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents. , 2022, 10, e004043.		34
4	Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients. Scientific Reports, 2022, 12, 5448.	3.3	5
5	Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma. Journal of Translational Medicine, 2022, 20, 159.	4.4	12
6	A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation. Journal of Translational Medicine, 2021, 19, 17.	4.4	6
7	No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study. Cancers, 2021, 13, 475.	3.7	20
8	Integrated Genomics Identifies miR-181/TFAM Pathway as a Critical Driver of Drug Resistance in Melanoma. International Journal of Molecular Sciences, 2021, 22, 1801.	4.1	20
9	Could asymptomatic carriers spread the SARS-CoV-2 infection? Experience from the Italian second wave. Journal of Translational Medicine, 2021, 19, 93.	4.4	3
10	Ipilimumab and Stereotactic Radiosurgery with CyberKnife® System in Melanoma Brain Metastases: A Retrospective Monoinstitutional Experience. Cancers, 2021, 13, 1857.	3.7	5
11	The Ratio of GrzB+ $\hat{\wedge}$ FoxP3+ over CD3+ T Cells as a Potential Predictor of Response to Nivolumab in Patients with Metastatic Melanoma. Cancers, 2021, 13, 2325.	3.7	7
12	Proteomics meets transcriptomics: Identification of tumor tissue signatures specific to anti-PD1 treatment in late-stage melanoma patients.. Journal of Clinical Oncology, 2021, 39, e21543-e21543.	1.6	0
13	Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy. Cancers, 2021, 13, 4164.	3.7	5
14	Clinical Outcome Prediction in COVID-19 Patients by Lymphocyte Subsets Analysis and Monocytes $\hat{\wedge}$ iTNF- $\hat{\pm}$ Expression. Biology, 2021, 10, 735.	2.8	4
15	A Psychosocial Genomics Pilot Study in Oncology for Verifying Clinical, Inflammatory and Psychological Effects of Mind-Body Transformations-Therapy (MBT-T) in Breast Cancer Patients: Preliminary Results. Journal of Clinical Medicine, 2021, 10, 136.	2.4	12
16	Bleeding in Plastic $\hat{\wedge}$ Aesthetic Surgery: A Prognostic Pathway with Clinical Application. Aesthetic Plastic Surgery, 2020, 44, 201-206.	0.9	5
17	Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients. Journal of Translational Medicine, 2020, 18, 121.	4.4	29
18	Multiplex immunohistochemistry assay to evaluate the melanoma tumor microenvironment. Methods in Enzymology, 2020, 635, 21-31.	1.0	2

#	ARTICLE	IF	CITATIONS
19	Bleeding in Plastic-Aesthetic Surgery: A Prognostic Pathway with Clinical Application. <i>Aesthetic Plastic Surgery</i> , 2020, 44, 1897-1897.	0.9	0
20	Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy. , 2020, 8, e001689.		33
21	761â€¦Potential predictive biomarkers of rapid progression and response to anti-PD1 treatment by gene profiling analysis in metastatic melanoma patients. , 2020, , .		0
22	229â€¦Discovery of ganglioside GM2 activator as a novel proteomic biomarker associated with response to treatment in first-line melanoma subjects treated with PD-1 immunotherapy. , 2020, , .		0
23	Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. <i>Cell Research</i> , 2019, 29, 846-861.	12.0	160
24	ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin. <i>Cancers</i> , 2019, 11, 1425.	3.7	22
25	Enzyme activity of circulating CD73 in human serum. <i>Methods in Enzymology</i> , 2019, 629, 257-267.	1.0	3
26	Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma. <i>Scientific Reports</i> , 2019, 9, 7449.	3.3	43
27	Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations. , 2019, 7, 91.		24
28	Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway. <i>Cancer Immunology Research</i> , 2019, 7, 841-852.	3.4	47
29	First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 765-772.	4.2	35
30	The ACC melanoma pilot project: â€œReal-worldâ€ evaluation of an NGS platform for molecular characterization of melanoma in Italy.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14600-e14600.	1.6	0
31	Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma. <i>Oncolmmunology</i> , 2018, 7, e1387706.	4.6	76
32	PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab. <i>Oncolmmunology</i> , 2018, 7, e1405206.	4.6	43
33	MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With BRAFV600E Mutation Detected in Circulating-Free DNA. <i>Frontiers in Pharmacology</i> , 2018, 9, 856.	3.5	68
34	Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. , 2018, 6, 74.		292
35	Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts. <i>Journal of Translational Medicine</i> , 2018, 16, .	4.4	2
36	CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab. <i>European Journal of Cancer</i> , 2018, 97, 59-61.	2.8	22

#	ARTICLE	IF	CITATIONS
37	Abstract 558: Prognostic gene signature use in checkpoint inhibitor monotherapy for melanoma. , 2018, , .		2
38	Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma. <i>Oncotarget</i> , 2018, 9, 18997-19005.	1.8	25
39	IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients. <i>OncoImmunology</i> , 2017, 6, e1261242.	4.6	59
40	Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab. <i>Journal of Translational Medicine</i> , 2017, 15, 244.	4.4	73
41	Translational significance of Nodal, Cripto-1 and Notch4 in adult nevi. <i>Oncology Letters</i> , 2016, 12, 1349-1354.	1.8	9
42	Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab. <i>Clinical Cancer Research</i> , 2016, 22, 4848-4858.	7.0	146
43	miR-579-3p controls melanoma progression and resistance to target therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E5005-13.	7.1	99
44	Melanoma and immunotherapy bridge 2015. <i>Journal of Translational Medicine</i> , 2016, 14, 65.	4.4	12
45	Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, .	4.4	2
46	Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients. <i>Journal of Translational Medicine</i> , 2015, 13, O8.	4.4	2
47	Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy. <i>OncoImmunology</i> , 2015, 4, e1008842.	4.6	72
48	Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for response biomarker identification. <i>Journal of Translational Medicine</i> , 2014, 12, O13.	4.4	1
49	MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPilimumab. <i>Journal of Translational Medicine</i> , 2014, 12, P11.	4.4	12
50	Immunoscore: a new possible approach for melanoma classification. , 2014, 2, .		9
51	Immunoscore as new possible approach for the classification of melanoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, e20020-e20020.	1.6	1
52	Effect of dabrafenib on melanoma cell lines harbouring the BRAF V600D/R mutations. <i>BMC Cancer</i> , 2013, 13, 17.	2.6	38
53	Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for clinical response biomarker identification. , 2013, 1, .		1
54	NF- κ B as potential target in the treatment of melanoma. <i>Journal of Translational Medicine</i> , 2012, 10, 53.	4.4	118